Stemline Therapeutics

News

Cancer therapy that zeroes in on stem cells seeks $50 million IPO

A biopharmaceutical company developing cancer therapies that zero in on cancer stem cells to treat brain cancer and acute myeloid leukemia is seeking to raise $50 million in an initial public offering. Cancer stem cells are viewed as highly malignant “seeds” of tumors, according to the company’s website. Although they account for 5 percent or […]